8NE Stock Overview A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Lisata Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Lisata Therapeutics Historical stock prices Current Share Price US$3.54 52 Week High US$3.66 52 Week Low US$2.22 Beta 1.14 1 Month Change 55.26% 3 Month Change 30.15% 1 Year Change 31.11% 3 Year Change -67.67% 5 Year Change -91.92% Change since IPO -99.48%
Recent News & Updates
Lisata Therapeutics, Inc. Announces Completion of Patient Enrollment in All Three Cohorts of the Phase 1b/2a Cendifox Trial Dec 11
Lisata Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 06
Lisata Therapeutics, Inc. Announces First Patient Treated in the Second-Line Cholangiocarcinoma Cohort of the BOLSTER Trial Sep 17
Lisata Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Aug 05
Lisata Therapeutics, Inc. Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma Jul 16
Lisata Therapeutics, Inc. Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in A Preclinical Model Jul 10 See more updates
Lisata Therapeutics, Inc. Announces Completion of Patient Enrollment in All Three Cohorts of the Phase 1b/2a Cendifox Trial Dec 11
Lisata Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 06
Lisata Therapeutics, Inc. Announces First Patient Treated in the Second-Line Cholangiocarcinoma Cohort of the BOLSTER Trial Sep 17
Lisata Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Aug 05
Lisata Therapeutics, Inc. Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma Jul 16
Lisata Therapeutics, Inc. Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in A Preclinical Model Jul 10
Lisata Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Lisata Therapeutics, Inc., Annual General Meeting, Jun 27, 2024 May 01
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma Apr 23
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma Apr 09
Lisata Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024 Feb 23
Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme Jan 18
Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma Dec 13
Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents Nov 04
New major risk - Revenue and earnings growth Nov 04
Lisata Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1 Oct 25
Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma Sep 07
Lisata Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 08
Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors Jul 12
Lisata Therapeutics Announces Enhancements to Ongoing Phase 2B Ascend Trial of LSTA1 May 25
Less than half of directors are independent Nov 16
Less than half of directors are independent Oct 12
Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc. Sep 17 Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.
Nasdaq Grants Caladrius Biosciences an Extension Through February 13, 2023 to Evidence Compliance with the Bid Price Requirement Aug 20
Caladrius Biosciences, Inc Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease Aug 03
Caladrius Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology Jul 07
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA(R) in Coronary Microvascular Dysfunction May 24
Caladrius Biosciences Inc. Announces IDMC Recommendation to Advance Clbs201 Trial for the Treatment of Diabetic Kidney Disease May 20
Caladrius Biosciences, Inc. (NasdaqCM:CLBS) entered into a definitive merger agreement to acquire Cend Therapeutics Inc. for $38.1 million. Apr 28
Insufficient new directors Apr 27
Caladrius Biosciences, Inc. Treats First Patient in the Phase 1B Trial of CLBS201 for the Treatment of Diabetic Kidney Disease Apr 13
Todd C. Girolamo Intent to Resign as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc., Effective March 14, 2022 Feb 27
Caladrius Biosciences to Assess Its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease Jun 23
Caladrius Biosciences, Inc. Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease Mar 10
Caladrius Biosciences, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
Caladrius Biosciences, Inc. announced that it has received $25 million in funding Jan 26
Caladrius Biosciences, Inc. announced that it expects to receive $25 million in funding Jan 22
New 90-day high: €2.84 Jan 21
Caladrius Biosciences, Inc. Treats First Patient in the Phase 2B Freedom Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction Jan 20
Caladrius Biosciences, Inc. Announces Executive Changes Nov 18
New 90-day low: €1.24 Nov 14
Caladrius Biosciences, Inc. Appoints Anne Whitaker to Board of Directors Nov 03
New 90-day low: €1.27 Oct 30
Caladrius Biosciences, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage Oct 10
Insider recently bought €85k worth of stock Sep 12
New 90-day low - €1.40 Sep 05
Caladrius Biosciences, Inc. to Report Q2, 2020 Results on Aug 13, 2020 Aug 07 Shareholder Returns 8NE DE Biotechs DE Market 7D 26.4% 5.8% 2.0% 1Y 31.1% -6.1% 9.6%
See full shareholder returns
Return vs Market: 8NE exceeded the German Market which returned 9.6% over the past year.
Price Volatility Is 8NE's price volatile compared to industry and market? 8NE volatility 8NE Average Weekly Movement 10.9% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 8NE's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8NE's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Show more Lisata Therapeutics, Inc. Fundamentals Summary How do Lisata Therapeutics's earnings and revenue compare to its market cap? 8NE fundamental statistics Market cap €30.35m Earnings (TTM ) -€20.11m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 8NE income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$20.74m Earnings -US$20.74m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 03:05 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lisata Therapeutics, Inc. is covered by 14 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jan Wald Benchmark Company Kumaraguru Raja Brookline Capital Markets Brian Kemp Dolliver Brookline Capital Markets
Show 11 more analysts 
